# Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer

> **NCT00556621** · PHASE1,PHASE2 · COMPLETED · sponsor: **Institut du Cancer de Montpellier - Val d'Aurelle** · enrollment: 14 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** cisplatin
- **DRUG:** gemcitabine hydrochloride
- **PROCEDURE:** biopsy
- **PROCEDURE:** cystoscopy
- **PROCEDURE:** therapeutic conventional surgery
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00556621
- **Lead sponsor:** Institut du Cancer de Montpellier - Val d'Aurelle
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2015-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00556621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00556621, "Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00556621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*